HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Expanding Crop Of Ingredients Could Shrink Support For Lawful Use Of Hemp In Supplements

Executive Summary

Groups of House and Senate members who opposed legislation to de-schedule hemp as a controlled substance in 2018 remain opposed to also legalizing cannabis and could stifle support for making lawful hemp’s use in supplements.

You may also be interested in...



Food In Capitol Hill's Lawful Hemp Recipe, But CBD, Delta-8 On FDA Unsafe Food Ingredients Menu

All legislation introduced in Congress on establishing hemp as lawful dietary ingredient also would extend change to food ingredients. Two hemp derivatives among 12 ingredients on FDA’s first list of food ingredients unsafe for use in food.

CBD Will Be US FDA’s ‘One’ Lawful Hemp Compound, House Appropriators Anticipate

Reference in report accompanying House Appropriation Committee bill for FDA FY2023 budget isn’t binding and wasn’t appropriators’ first mention of agency’s response to de-scheduling hemp as a controlled substance. But their ’ statement was more pointed than in previous appropriation reports.

Is Delta-8 Hemp? No, But It's Not As ‘Scary’ As Other Cannabinoids With Higher THC Levels

Other cannabis derivatives some businesses may attempt to sell as meeting statutory definition for hemp fare worse in review consultant Deborah Miran presented during FDLI webinar on delta-8’s status as a dietary ingredient.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel